Drug
ACE1831
ACE1831 is a pharmaceutical drug with 3 clinical trials. Currently 2 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
2(67%)
Phase Distribution
Ph phase_1
2
67%
Ph not_applicable
1
33%
Phase Distribution
2
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(3)
Detailed Status
Recruiting2
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Phase 12 (66.7%)
N/A1 (33.3%)
Trials by Status
recruiting267%
not_yet_recruiting133%
Recent Activity
2 active trials
Showing 3 of 3
recruitingphase_1
Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
NCT07061938
not_yet_recruitingnot_applicable
ACE1831 in Adult Subjects With Relapsed/Refractory Systemic Lupus Erythematosus （SLE）
NCT07314567
recruitingphase_1
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
NCT05653271
Clinical Trials (3)
Showing 3 of 3 trials
NCT07061938Phase 1
Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
NCT07314567Not Applicable
ACE1831 in Adult Subjects With Relapsed/Refractory Systemic Lupus Erythematosus （SLE）
NCT05653271Phase 1
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3